Symptomatic Carotid Outcomes Registry
Ischemic Stroke | Transient Ischemic Attack | Carotid StenosisThe purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinical features will be \<5%.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
40 and up
Participation Criteria
Inclusion Criteria:
* Age ≥40 years plus stroke or TIA ipsilateral to 50-99% ICA stenosis
In addition, patients must have at least one clinical or radiologic marker of reduced stroke risk
Clinical Reduced Stroke RISK:
1. Retinal ischemia only (amaurosis fugax, branch retinal artery occlusion (BRAO), central retinal artery occlusion (CRAO)
2. Female sex
3. Most recent stroke or TIA \>1 week ago
Radiologic Reduced Stroke RISK:
1. Transcranial Doppler (TCD) study demonstrating lack of microembolic signals
2. Cross-sectional MRI plaque imaging demonstrating absence of intraplaque hemorrhage
3. For patients with TIA: brain MRI shows no DWI lesion
Exclusion Criteria:
Atrial fibrillation or other high-risk sources of cardiac embolism unless it is device detected AF only or duration \<6 minutes
Alcohol and substance abuse within the prior 24 months
Clinically significant bleeding diathesis (platelet count \<100K, prothrombin time \>14 seconds)
Clear indication for therapeutic anticoagulation (for example, DVT or pulmonary embolism within past 3 months)
Left ventricular ejection fraction \<20%
Known allergy or intolerance to aspirin or clopidogrel
Life expectancy less than 12 months
Moderate/severe dementia (Mini-mental or MOCA score \<22
Modified Rankin score of \>4
Nonatherosclerotic cause of carotid stenosis
Most recent symptomatic event \>180 days from the time of enrollment
-
Study Location
Calgary Health Sciences Center
Calgary Health Sciences CenterCalgary, Alberta
Canada
Contact Study Team
Bijoy Menon, MD
Western University/London Health Sciences Center
Western University/London Health Sciences CenterLondon, Ontario
Canada
Contact Study Team
Luciano Sposato, MD
University of Manitoba
University of ManitobaWinnipeg, MN
Canada
Contact Study Team
Nishita Singh, MBBS
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
Brian Buck, MD
Northern Ontario School of Medicine
Northern Ontario School of MedicineSudbury, Ontario
Canada
Contact Study Team
Serena Saini
Vancouver General Hospital
Vancouver General HospitalVancouver, British Columbia
Canada
Contact Study Team
Thalia Field, MD
- Study Sponsored By
- University of Maryland, Baltimore
- Participants Required
- More Information
- Study ID:
NCT05300737